PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive Officer, will participate in the following investor conferences during the month of December:
- 27th Annual Piper Jaffray Healthcare Conference
New York, NY
December 2, 2015
Fireside Chat will be held at 11:50 AM ET and will be webcast live on the internet.
To access the webcast, please visit the Investors Relations section of the Company's website at www.agiletherapeutics.com.
- 2015 RBC Capital Market’s Healthcare Investor Day
December 10, 2015
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Contact: Mary Coleman -- 609-356-1921